Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Carfilzomib
Drug ID BADD_D00367
Description Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.[L39392]
Indications and Usage Carfilzomib is indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy. Approval is based on response rate.
Marketing Status Prescription
ATC Code L01XG02
DrugBank ID DB08889
KEGG ID D08880
MeSH ID C524865
PubChem ID 11556711
TTD Drug ID D00UVA
NDC Product Code 50384-0180; 52076-6251; 76075-103; 50384-0230; 54893-0037; 76055-0035; 63552-009; 16436-0116; 63552-035; 50384-0260; 55111-985; 11722-059; 50384-0220; 50384-0210; 50384-0190; 67262-0010; 76075-102; 50384-0240; 42385-731; 76075-101
Synonyms carfilzomib | PR-171 | PR171 | Kyprolis
Chemical Information
Molecular Formula C40H57N5O7
CAS Registry Number 868540-17-4
SMILES CC(C)CC(C(=O)C1(CO1)C)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(C)C)NC(=O)C(CCC3=CC=CC=C3) NC(=O)CN4CCOCC4
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Blood urea increased13.13.01.0060.001332%Not Available
Body temperature increased13.15.01.0010.001332%Not Available
Bone neoplasm16.29.01.001; 15.09.02.0010.000533%Not Available
Bone pain15.02.01.0010.004529%
Bradycardia02.03.02.002--Not Available
Bronchitis22.07.01.001; 11.01.09.0010.003463%
Burning sensation17.02.06.001; 08.01.09.0290.002398%Not Available
C-reactive protein increased13.09.01.007--Not Available
Capillary leak syndrome24.06.03.001; 08.01.07.0120.000139%
Cardiac arrest02.03.04.001--
Cardiac failure02.05.01.0010.004795%
Cardiac failure acute02.05.01.0050.001066%Not Available
Cardiac failure congestive02.05.01.0020.008525%Not Available
Cardiac hypertrophy02.04.02.0170.000533%Not Available
Cardio-respiratory arrest22.02.06.007; 02.03.04.0020.000625%Not Available
Cardiogenic shock02.05.01.003; 24.06.02.0060.000799%Not Available
Cardiomegaly02.04.02.0010.000347%Not Available
Cardiomyopathy02.04.01.0010.003197%Not Available
Cardiovascular disorder24.03.02.009; 02.01.01.0010.000556%Not Available
Cataract06.06.01.0010.002131%
Cellulitis23.09.01.001; 11.02.01.0010.002398%Not Available
Cerebral haemorrhage24.07.04.001; 17.08.01.003--Not Available
Cerebral ischaemia24.04.06.003; 17.08.01.0050.000799%
Cerebral thrombosis17.08.01.006; 24.01.04.0030.000139%Not Available
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Chest discomfort22.02.08.001; 08.01.08.019; 02.02.02.0090.003730%Not Available
Chest pain08.01.08.002; 02.02.02.011; 22.02.08.0030.009324%Not Available
Chills15.05.03.016; 08.01.09.0010.008525%
Choking22.02.05.0010.000533%Not Available
Chronic obstructive pulmonary disease22.03.01.007--Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 18 Pages